reported that BMI1 constitutes a major epigenetic vulnerability in H3K27M-DIPG cells and that the combination of the BMI1 inhibitor PTC028 with the senolytic drug obatoclax is a promising therapeutic strategy for DIPG (13). This evidence concerns the gene BMI1 and diffuse intrinsic pontine glioma.